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ABSTRACT Nosocomial outbreaks of vancomycin-resistant Enterococcus faecium (VREfm) are thought to occur by transmission
of VREfm between patients, predicting that infection control interventions will limit cross-transmission. Despite implementa-
tion of such strategies, the incidence of VREfm infections continues to rise. We aimed to use genomics to better understand the
epidemiology of E. faeciumwithin a large hospital and investigate the reasons for failure of infection control strategies. Whole-
genome sequencing was performed on 61 E. faecium (36 VREfm) isolates, predominately from blood cultures collected at a sin-
gle hospital between 1998 and 2009, and on five vanB-positive anaerobic commensal bacteria isolated from human feces. Phylog-
enomic analysis and precise mapping of the vanB gene, which contains the Tn1549 transposon, showed that at least 18 of the 36
VREfm isolates had acquired the transposon via independent insertion events, indicating de novo generation of VREfm rather
than cross-transmission. Furthermore, Tn1549 sequences found in 15 of the 36 VREfm isolates were the same as the Tn1549 se-
quence from one of the gut anaerobes. National and international comparator E. faecium isolates were phylogenetically inter-
spersed with isolates from our hospital, suggesting that our findings might be globally representative. These data demonstrate
that VREfm generation within a patient is common, presumably occurring in the human bowel during antibiotic therapy, and
help explain our inability to reduce VREfm infections. A recommendation from our findings is that infection control practices
should include screening patients for specific hospital clones of vancomycin-susceptible E. faecium rather than just VREfm.
IMPORTANCE Enterococcus faecium is an increasingly important human pathogen causing predominantly antibiotic-resistant
infections in hospitalized patients. Large amounts of health care funding are spent trying to control antibiotic-resistant bacteria
in hospitals globally, yet in many institutions around the world, vancomycin-resistant E. faecium (VREfm) infections continue
to rise. The new findings from this study help explain the failures of our current approaches to controlling vanBVREfm in health
care institutions. Given the importance of this bacterium as a cause of hospital-acquired infections and the difficulties faced by
infection control units in trying to prevent colonization in their institutions, the novel findings from this study provide evidence
that a new approach to controlling VREfm in hospitals is required. In particular, more attention should be given to understand-
ing the epidemiology of hospital-adapted vancomycin-susceptible E. faecium, and patients at higher risk for de novo generation
of VREfm need to be identified and optimally managed.
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Controlling increasing antimicrobial resistance in clinically im-portant bacteria is a key challenge for clinicians and scientists,
and there is an urgent need to prevent the emergence and subse-
quent spread of resistant isolates. Enterococcus faecium is a pri-
mary example of one such troublesome pathogen; while innately
resistant to many classes of antibiotics, this bacterium has dem-
onstrated a remarkable capacity to evolve new antimicrobial re-
sistances. In fact, E. faecium has been highlighted by the Infectious
Diseases Society of America as one of the key problem bacteria, or
ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter species) pathogens, requiring new therapies (1),
and there has been a steadily increasing prevalence of E. faecium-
related nosocomial infections (2).
Millions of dollars are spent each year by health care systems
trying to contain antibiotic-resistant bacteria and prevent cross-
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transmission. Nosocomial outbreaks of vancomycin-resistant en-
terococci (VRE) are thought to occur when a patient already car-
ryingVRE in his/her bowel shedsVRE,which are then transmitted
by health care workers or via the environment to other patients
(3). Thismodel predicts that interventions based on screening and
isolation of VRE-colonized patients, improved hand hygiene, and
enhanced hospital cleaning will limit cross-transmission (4). In-
terestingly, interventions at one U.S. hospital based on modified
use of antibiotics have also been associated with reducing VRE
transmission (5). At the Austin Hospital in Melbourne, Australia
(an 800-bed tertiary referral institution), hand hygiene schemes
have resulted in a significant reduction in the incidence of
methicillin-resistant S. aureus (MRSA); however, the incidence of
VRE has continued to rise (6). A similar story has unfolded in
other regions, with VRE now being responsible for over 30% of
E. faecium bacteremias in some European countries (7) and for
outbreaks in other European countries, Asia, and the United
States (8–11). In the United Kingdom, concern about increasing
VRE incidence led to mandatory reporting of rates of VRE bacte-
remia, and more than 500 cases per year have been reported since
2004 (http://www.hpa.org.uk/; accessed, 3 December 2012).
Clinically significant VRE strains were first reported from Eu-
rope and the United Kingdom in 1986 and in the United States
soon after (12–14). Glycopeptide resistance in enterococci is me-
diated predominantly by mobile gene clusters that confer resis-
tance to vancomycin and teicoplanin (vanA genotype) or vanco-
mycin only (vanB genotype) (15). In the United States, vanA-
containing VRE dominate, in Europe, a mix of vanA and vanB-
containing VRE is found, while in Australia, vanB-containing
VRE dominate (16–18). Nonenterococcal species (predominately
anaerobes) may carry the vanB resistance determinant as part of
transposon Tn1549 (19) in the human bowel, and in Australia,
while carriage of vancomycin-resistant E. faecium (VREfm) in the
general community is rare, up to 50% of healthy adults have de-
tectable vanB in their fecal samples as determined by PCR (20, 21).
This unexpected finding has also been reported in Canada (22).
Transmission of a Tn1549-like element from one human fecal
anaerobe, Clostridium symbiosum MLG101, to Enterococcus fae-
cium and Enterococcus faecalis in the digestive tracts of mice has
been demonstrated, suggesting that the same processmay occur in
the human bowel (23).
Recently, the first complete genome sequences of E. faecium
have been reported (24, 25), and draft genomes of additional
E. faecium isolates have been studied to explore antibiotic resis-
tance mechanisms and phylogenomic relationships (26–29).
Hospital-associated ampicillin-resistant E. faecium isolates, which
are represented by three dominant sequence types (ST17, ST18,
and ST78; ST203 is an ST78 single-locus variant [SLV]), are ge-
netically distinct and replace the normal reservoir of ampicillin-
susceptible E. faecium strains in hospitalized patients (24, 25, 30).
These three sequence types have been collectively referred to as
clonal complex 17 (CC17); however, the growing realization of
the significant impact of recombination on the evolution of E. fae-
cium suggests that the CC designation may not be accurate (31,
32) because of the significant genetic variation that has been re-
vealed among these hospital-associated isolates (33). Because of
the failure of intense infection control interventions to curtail
the rise of VRE, we applied genome sequencing and detailed com-
parative genomic analysis to a collection of E. faecium isolates
to better understand the relationship between vancomycin-
susceptible E. faecium (VSEfm) andVREfm isolates and to test the
hypothesis that de novo generation of VREfm is a frequent occur-
rence that is undermining infection control efforts.
RESULTS
In this study, we sequenced and compared the genomes of 61
E. faecium isolates. Fifty-six were bloodstream isolates from
unique patients over a 12-year period in a single institute in Mel-
bourne, Australia (32 VREfm and 24 VSEfm isolates), 3 were
rectal-screening isolates from Royal Perth Hospital in western
Australia (all VREfm), and 2 were clinical isolates from Royal
Darwin Hospital, Darwin, Northern Territory, Australia (1
VREfm and 1 VSEfm isolate). Relevant epidemiological informa-
tion and a summary of sequencing results are presented in Data-
set S1 in the supplemental material. The AUS0004 (ST17) (24)
and AUS0085 (ST203) (Margaret M. C. Lam, Torsten Seemann,
Nicholas J. Tobias, Honglei Chen, Volker Haring, Robert J.
Moore, Susan Ballard, M. Lindsay Grayson, Paul D. R. Johnson,
Benjamin P.Howden, andTimothy P. Stinear, submitted for pub-
lication) genome sequences were used as primary references, and
two publicly available international E. faecium blood culture iso-
lates were included for comparison: the ST18 DO (TX16) strain
isolated from Texas in 1998 (25) and the ST203 strain 1,231,502
from the Broad Institute collection (26). In addition, five anaero-
bic bacteria previously isolated from human feces and demon-
strated to carry Tn1549 within the vanB operon were also sub-
jected to genome sequencing to allow comparison of the vanB
transposon sequences from these anaerobes and the VREfm iso-
lates. The details and sequencing results for these isolates are sum-
marized in Dataset S2 in the supplemental material.
To address the question of whether patients develop VREfm
within their bowel or acquire VREfm from an exterior source, we
first conducted a detailed analysis of the characteristics of the
Tn1549 transposon among the vanB-positive isolates. In our re-
cent comparison of the ST203 VREfm (AUS0085) and ST17 VRE
(AUS0004) whole genomes (Margaret M. C. Lam, Torsten See-
mann, Nicholas J. Tobias, Honglei Chen, VolkerHaring, Robert J.
Moore, Susan Ballard, M. Lindsay Grayson, Paul D. R. Johnson,
Benjamin P.Howden, andTimothy P. Stinear, submitted for pub-
lication), we identified a number of Tn1549 features that would
permit identification of unique transposon acquisition events, in-
cluding transposon sequence type, insertion site, insertion direc-
tion, and coupling sequence composition (Fig. 1). Analysis of the
FIG 1 Schematic of the Tn1549 characteristics of E. faecium isolates in this
study. Characteristics used to identify unique Tn1549 transmission events in
vanB-containing E. faecium isolates, including a unique transposon sequence
(1), an insertion site (2), the insertion orientation (3), and the flanking cou-
pling sequence (4). Flanking imperfect left and right inverted repeat (IR-L and
IR-R) insertion sites are highlighted in orange and blue, respectively. The vanB
locus contains vancomycin resistance genes (green), which are conserved in all
vanB sequence types, as well as other genes, which leads to variation in total
transposon size, as indicated.
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36 VREfm isolates and the anaerobic bacteria in this study found
that 15 VREfm isolates harbored a larger 57-kb version of Tn1549
than the other isolates (Fig. 2). The Tn1549 phylogeny, inferred by
comparing the 118 variable nucleotides within this element
among all isolates (Fig. 3A), revealed two dominant populations
of Tn1549, those represented by the sequences from the short,
33-kb element from AUS0069 and those represented by the 57-kb
element from AUS0085. Overall, there were five different trans-
poson sequence groups among the 36 VREfm isolates (based on a
difference of three or more single nucleotide polymorphisms
[SNPs]) (Fig. 3A). Notably, Tn1549 sequences identified in the
anaerobic bacteria were similar to those from VREfm isolates.
Remarkably, the Tn1549 sequence from Clostridium sp. strain
MLG055, isolated from the feces of a dialysis patient in Mel-
bourne, Australia (20), was identical to Tn1549 from a number of
VREfm isolates from bloodstream infections, indicating that
transfer of this element among the bowel microbiota may occur.
The chromosomal insertion site of all Tn1549-like elements for
the 36 VREfm isolates was investigated, revealing a restricted rep-
ertoire of insertions, indicating that Tn1549 insertion is not ran-
dom (Fig. 3B). Notably, the VREfm isolates contained only a sin-
gle copy of Tn1549. Seven different chromosomal insertion sites
were identified, yet transposons of the same sequence were con-
sistently inserted at the same chromosomal location (Fig. 3A and
B). For example, transposons represented by isolate 69 (red in
Fig. 3A) all integrated within EFAU004_00592, while transposons
represented by isolate 85 (blue in Fig. 3A) all integrated within the
signal peptidase I gene (EFAU004_00734). In conjunction with
the core genome phylogeny (see below), we then used Tn1549
sequence type, site of insertion, insertion orientation, and cou-
pling sequence to distinguish inherited from independent Tn1549
acquisitions among E. faecium isolates (Fig. 1 and 3).
To understand the population structure of the E. faecium
strains included in this study, a core genome E. faecium phylogeny
was constructed using 14,988 SNPs identified among the 63 iso-
lates (excluding insertions and deletions). Split decomposition
analysis produced a reticulate phylogeny, suggesting that recom-
bination contributes to the phylogenetic signal (data not shown).
Because recombination would perturb the phylogeny, we em-
ployed an iterative algorithm that searched for a high density of
SNPs and excluded chromosome regions likely acquired by re-
combination (Fig. 4). This analysis predicted 297 recombination
events, spanning 1.3 Mb (44% of the chromosome) and account-
ing for 12,849 SNPs (85.7% of all nucleotide variation). The re-
maining 2,139 SNPswere aligned among all isolates, and a treewas
inferred using maximum likelihood based on these vertically in-
herited base substitutions alone (Fig. 3C).
Isolates generally clustered within their previously defined
multilocus sequence types (MLSTs); however, there were also
some clear exceptions highlighting the impact of recombination
events on MLSTs. Five of the seven MLST loci were impacted by
recombination (Fig. 4). For example, isolates 69 (SLV of ST252)
and 71 (ST252) clustered among the ST203 isolates based on the
nonrecombinant core genome analysis (Fig. 4). As expected, the
non-CC17 isolates (isolates 10, 92, and 101) were more distantly
related to all other isolates. Significantly, CC17 VSEfm isolates
were closely related to, and in some cases essentially indistinguish-
able from, CC17 VREfm isolates at this core genome level, sug-
gesting that the CC17 VSEfm and CC17 VREfm strains were part
of the same circulating population rather than that they evolved
independently. Thus, the evolution of VREfm strains from colo-
nizing VSEfm strains, and not just the clonal spread of VREfm
strains, explains the epidemiology of invasive VREfm disease ob-
served in this study, suggesting that the epidemiology of VSEfm in
FIG 2 Comparison of Tn1549 sequences. DNA-DNA comparison of Tn1549 sequences (33 kb, short version [S]) from AUS0004 and AUS0085 (57 kb, long
version [L]), visualized with the Artemis Comparison Tool, showing the location of the vanB locus in both elements (orange shading) and the putative novel
conjugation locus (pink shading) in the long version of Tn1549. Dark-blue shading indicates regions of DNA identity. Percentages of GC content (500-bp sliding
window) are shown above, followed by heatmap visualizations of results of read mapping normalized to both AUS0004 and AUS0085 for a representative
selection of VREfm and vanB-positive bowel anaerobes. Note that changes in read mapping density across Tn1549 are explained by sequencing biases, as these
regions correlate with significant changes in GC content.
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FIG 3 Phylogeny of Tn1549 elements and Enterococcus faecium. (A) SNP-based phylogeny of Tn1549 elements in E. faecium and anaerobes (red dots indicate
anaerobes). The color scale represents the Tn1549 sequence type (based on SNP analysis) as well as the transposon insertion site in the E. faecium chromosome,
relative to the AUS0004 chromosome sequence. Black bars within the red transposon sequence groups represent single nucleotide differences. The coupling
sequence is the 5- to 8-bp sequence introduced from the donor during transposition (“” refers to the site of insertion, as shown in Figure 1; * indicates
nucleotide deletion). Isolates shaded in pink contain the shorter (33-kb) version of Tn1549, while those in blue contain the longer (57-kb) version of Tn1549. (B)
Overview of the seven unique transposon insertion sites for the 36 VREfm clonesmapped to the AUS0004 chromosome, as well as the transposon sequence type.
The color scheme follows that described in panel A. Outter numbers indicate numbers of isolates with insertions at that position. Inner numbers indicate the
insertion position in the AUS0004 chromosome. (C) Maximum-likelihood phylogeny for E. faecium based on SNPs in the core genome, with major multilocus
sequence type groups highlighted. Isolates from other institutions are highlighted in yellow and include five isolates from other institutions in Australia (RPH
(Continued)
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hospitals is a key factor driving the emergence of clonally related
VREfm.
In addition to examining the evolutionary relationship be-
tween the isolates based on a core genome, we also assessed an
E. faecium pan genome which included plasmids, prophages, and
other genomic elements (Dataset S3 in the supplemental material
and Fig. 5). The pan genome included more than 5 Mb of se-
quence bearing5,000 genes and demonstrated that even among
isolates that were found to be very closely related based on their
core genomes, variability in gene content was detected. For exam-
ple, isolates 73 and RPH3 had closely related core genomes; how-
ever, isolate 73 harbored a unique region (EFPAN04301 to EF-
PAN04389) that likely represented a plasmid with a large number
of hypothetical proteins and plasmid-associated genes. Similarly,
isolates 72 and 78 displayed closely related core genomes, with
isolate 72 harboring Tn1549 and isolate 78 lacking this element
but possessing a unique prophage (EFPAN02546 to EFPAN
02583).
In some cases, the VREfm phylogeny was suggestive of clonal
dissemination of an extant VREfm clone. For example, the ST203
cluster that included isolates 149, 86, 85, 81, 77, 93, and 96 was
isolated over a 12-month period from patients in the same hospi-
tal (Fig. 3C). Inspection of the pan genomes for these isolates
(Fig. 5) suggests that they may have been transmitted directly be-
tween patients, except for isolates 86 and 96, where differences in
gene content, possibly due to plasmid acquisition, were detected.
For example, isolate 86 contained the genes EFPAN04820 to EF-
PAN04855, encoding a number of hypothetical proteins and a
type IV secretion system, while isolate 96 harbored a unique re-
gion (EFPAN04913 to EFPAN04927). In contrast, we were able to
combine the detailed transposon analysis with the core genome
phylogeny to define independent episodes of VREfm evolution
(Fig. 3C).
At least 18 distinct episodes of VREfm evolution of the total 36
VREfm isolates were detected, indicating that de novo evolution of
VREfm strains is an important source of VREfm infection at our
hospital. For example, the ST17 isolates 4 and 21 are closely related
at the core genome level, but their transposon sequence and inser-
tion sites are different. Furthermore, the dominant “red-orange”
and “blue-aqua” Tn1549 types are dispersed throughout the
E. faecium core genome phylogeny and can be explained by in-
stances of independent Tn1549 acquisition (Fig. 3C). In the ST252
cluster, four VREfm bloodstream isolates were sequenced from
Figure Legend Continued
isolates from Perth; isolates 928 and 755 from Darwin) and two isolates from the United States sequenced by others (DO, 1-231-502). Colored bars indicate
transposon sequences and insertion sites as defined for panel A.Gray triangles indicate predicted independentVREfm clones based onTn1549 characteristics and
core genome phylogeny. The node represented by the black circle shows the estimated divergence date for these ST17 and ST252 isolates, as inferred by
Path-O-Gen.
FIG 4 Recombination in E. faecium. Areas of predicted recombination in the E. faecium chromosome are highlighted, based on SNP density. MLST alleles are
indicated by triangles. Only purK and adk are in regions without predicted recombination. Two isolates (69 and 71, circled) are part of the ST252 complex by
MLST but cluster with the ST203 isolates based on core genome SNP analysis. Regions in red are recombinant inmultiple isolates in the collection, while regions
in blue are unique to one strain.
Genomics of VREfm
July/August 2013 Volume 4 Issue 4 e00412-13 ® mbio.asm.org 5
our hospital, and at least three of these indicate the independent
evolution of VREfm strains.
In the 33-month period fromMarch 2007 to November 2009,
we had an outbreak of clinical VRE infection at our institution (6).
Based onMLST analysis, it appeared that we had a clonal outbreak
ofVREfmdue to the introduction of a new clone of ST203VREfm.
However, analysis of the ST203 VREfm genome data from these
isolates demonstrates that at least 9 unique clones of ST203
VREfm have emerged (out of the 22 sequenced). These unique
ST203 VREfm isolates highlight the polyclonal nature of VREfm
at our hospital, even within a single MLST cluster that was first
detected as late as 2007.
In order to determine if these observations were unusual and
restricted to our hospital, we included genome sequences from
geographically dispersed E. faecium isolates for comparison. The
more recent isolates from other Australian cities were closely re-
lated to ST203 and ST252 isolates from our institution (high-
lighted in yellow in Fig. 3C). The older ST18 VREfm isolate from
the United States (DO strain, 1998) was more distantly related to
the majority of E. faecium isolates in this study. The recent VRE
isolate 1-231-502 (2008) was very similar to ST203 isolates from
our institution, suggesting global dissemination of this E. faecium
clone.
The collection of E. faecium isolates from a single hospital over
a 12-year period allowed us to analyze the evolutionary changes
and mutation rate in the isolate collection. For this analysis, we
used only ST17 and ST252 isolates from our institution, because
theywere isolated throughout the 12-year study period. This anal-
ysis revealed a strong molecular clock signal (Fig. 6) and allowed
estimation of a core genome mutation rate of 1.5  106 substi-
tutions per site per year or ~5 SNPs per genome per year (exclud-
ing SNPs introduced via recombination). This analysis suggested
that the ST17/ST252 isolates from the collection arose from a
common ancestor that existed in the late 1970s.
DISCUSSION
Using large-scale comparative genomics, we have demonstrated
that hospital vanBVREfm epidemiology is farmore complex than
previously recognized and is significantly driven by de novo
VREfmgeneration rather than simply nosocomial transmission of
extant VREfm strains.We found thatmany distinct clones of vanB
VREfm were responsible for bloodstream infection isolates from
patients at our institution. In fact, at least 18 of 36 VREfm isolates
FIG 5 E. faecium pan genome. Blue bar indicates the 5.4-Mb E. faecium pan genome, including 5,000 annotated genes, detected among genomes analyzed in this
study. A heat map shows the presence (black) and absence (white) of the 5,000 genes. Dataset S3 in the supplemental material summarizes the variable regions
and pan-genome contents for all isolates and includes EFPAN locus tags for all predicted coding sequences.
FIG 6 Evolution of E. faecium ST17 and ST252 isolates. Estimate of the
divergence date for ST17 and ST252 isolates by branch-to-tip analysis using
Path-O-Gen and branch lengths inferred by maximum-likelihood analysis
(http://tree.bio.ed.ac.uk/software/pathogen/).
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sequenced in this study were due to unique VREfm evolution
events. This includes a time period where a new sequence type of
E. faecium (ST203) emerged in our institution and causedwhat we
thought was a clonal outbreak (6). Additionally, circulating clones
of VSEfm and VREfm were phylogenetically intermingled. These
findings indicate that unique VREfm evolution events are com-
mon, presumably occurring in the human bowel, and taken to-
gether suggest that control strategies based on screening for
VREfm and isolation of colonized patients might not be com-
pletely effective.
We identified a number of Tn1549 features that could be uti-
lized to determine independent VREfm acquisition events
(Fig. 1), demonstrating the power of genome sequencing to un-
cover complex relationships between bacteria. Significantly, the
transposon sequences from anaerobic bacteria isolated from hu-
man feces were very similar and, in one case, identical to those
from VREfm isolates associated with bloodstream infections in
humans, suggesting that anaerobic bacteriamight form an impor-
tant component of the Tn1549 reservoir. If the transposon pool is
restricted and the VSEfm population is highly clonal, as occurs in
hospitalized patients (30), even unique in vivo generation episodes
of VREfm may appear like clonal spread of preformed VRE. This
issue was highlighted by detailed analysis of three ST203 isolates,
149, 86, and 96. Based on core genome phylogeny and transposon
analysis, these isolates appeared clonal; however, analysis of the
pan-genome components of these isolates (Fig. 5) demonstrated
additional genome diversity, in some cases driven by acquisition
of plasmids.While it is possible that individual genome variability
evolved in a clonally disseminated preformed VREfm strain, it is
also possible that clonally dispersed (but not identical) VSEfm
isolates have independently acquired an identical Tn1549 ele-
ment. If this is the case, then even more than 18 of the 36 VREfm
isolates sequenced in this study may have evolved independently.
While we focused our investigation on a single institution with
the primary aim of understanding the persistent VREfm outbreak
that we had noted, we included isolates from other Australian
cities and the United States. Sequences from these isolates were
very closely related to VREfm isolates from our institution inMel-
bourne, Australia, including the United States isolate (1,231,502).
Hospital-hospital transfer of colonized patients may explain this
observation in Australia; however, such movements are infre-
quent between Darwin and Melbourne. In our view, the best
model which explains our observations is silent circulation inter-
nationally of closely related VSEfm isolates, with local Tn1549
transposition events, which then lead to the appearance of new
clinical cases of VRE colonization and infection in hospitals.
The E. faecium genome is known to have high rates of recom-
bination, especially compared to other important hospital patho-
gens, such as Staphylococcus aureus (25, 34, 35). Here we applied
whole-genome sequencing and SNP clustering analysis to infer a
phylogeny and predict regions of recombination within the 63
E. faecium genomes used in this study (Fig. 3 and 4). A total of
1.3Mb (44%) of the chromosome was affected by recombination.
This includes five of the seven MLST loci (Fig. 4), indicating that
MLST analysis of E. faecium based on the currently selected alleles
may givemisleading results andmust be interpretedwith care.We
also defined an E. faecium pan genome, which includes 1,872 core
genes as well as 3,128 accessory genes identified within the 63
E. faecium isolates in this study (Fig. 5). This indicates significant
plasticity within the E. faecium genome, with large accessory ele-
ments potentially impacting the clinical behavior of these isolates,
as previously suggested (25, 33). Clonal complex 17 E. faecium
emerged as an important hospital-associated pathogen in the
1980s (36). By analyzing the ST17/ST252 isolates from this study,
we found a mutation rate in the core genome of 5 SNPs per ge-
nome per year and predicted that the common ancestor strain for
E. faecium at our institution existed around 1978 (95% confidence
interval [CI], 1973 to 1983), in keeping with the appearance of
CC17 E. faecium and VREfm in the 1980s.
Our findings have implications for the control of VREfm in
hospitals, where generation of new VREfm clones is a frequent
event. Because a high proportion of hospital patients carry non-
enterococcal vanB-containing organisms in their bowels (19, 20,
22, 37), we suggest that specific VSEfm clones should also be tar-
gets for control in the hospital environment. It remains to be
determined if hospital-associated VSEfm is acquired nosocomi-
ally by patients, as suggested in European studies, or if in fact these
isolates of VSEfm are present in the community in Australia (30,
38). A complete understanding of VSE epidemiology and the bi-
ology of the Tn1549 elementwill be critical to improving strategies
to curtail the VRE epidemic. These data dictate that alternative
strategies directed at identifying and isolating patients colonized
with high-risk VSEfm clones, identifying patients who harbor
vanB-containing Tn1549 and who are likely at increased risk of in
vivo generation, and identifying and modifying the selective pres-
sures promoting in vivo evolution are needed to prevent the on-
going emergence of VREfm as a public health threat.
MATERIALS AND METHODS
Bacterial isolates. Isolates used in this study were vancomycin-
susceptible and -resistant Enterococcus faecium strains recovered between
1998 and 2009 from blood culture specimens at Austin Health, a tertiary
referral hospital inMelbourne, Australia. Additionally, five recent clinical
and screening isolates of VSEfm and VREfm from other cities in Australia
(Darwin and Perth) were included for comparison, as were five previously
identified and characterized human bowel anaerobes containing Tn1549
within their vanB operon that were isolated in Melbourne, Australia (19,
20). All VREfm isolates were found to display the vanB genotype, as de-
termined by PCR (17). Enterococcus faecium isolates were previously an-
alyzed by MLST and were found to belong predominately to clonal com-
plex 17 (CC17) (6). Epidemiological data, including date and location of
isolation, were recorded. A summary of isolates and epidemiological data
is provided in Dataset S1 (E. faecium) and Dataset S2 (anaerobes) in the
supplemental material.
Genome sequencing and analysis.Genomic DNAwas extracted, and
all isolates were subjected to whole-genome shotgun sequencing using an
Illumina HiSeq-2000 sequencing system and 100-bp-paired-end TruSeq
chemistry or Ion Torrent single-end 100-bp or 200-bp sequencing chem-
istry (39) (Datasets S1 and S2). A read mapping approach was used to
align the sequences from these isolates with the recently completed E. fae-
cium ST203 genome, AUS0085 (Margaret M. C. Lam, Torsten Seemann,
Nicholas J. Tobias, Honglei Chen, Volker Haring, Robert J. Moore, Susan
Ballard, M. Lindsay Grayson, Paul D. R. Johnson, Benjamin P. Howden,
and Timothy P. Stinear, submitted for publication), using SHRiMP v2.0
(40). Single nucleotide polymorphisms (SNPs) in the E. faecium core ge-
nome were identified using Nesoni v0.93, which aligns the read of each
genome to that of the reference to construct a tally of putative differences
at each position (http://www.bioinformatics.net.au). In order to exclude
regions of suspected recombination from the phylogenomic analysis, re-
gions with high frequencies of polymorphic nucleotides were removed
from the alignment, as previously described (41, 42), and a phylogeny was
inferred using maximum likelihood with RAxML (43). The temporal sig-
nals in the sequence datawere analyzed using Path-O-Gen (http://tree.bio
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.ed.ac.uk/software/pathogen/). SNPs likely introduced via recombination
were identified using the method described in Croucher et al. (41).
To investigate the total E. faecium gene content, an E. faecium pan
genome was defined after de novo assembly using Velvet v1.2.04 (44) and
alignment of contigs to the AUS0085 genome using MUMmer (45). Un-
aligned contigs were appended to theAUS0085 genome to construct a pan
genome, which was annotated using Prokka (http://bioinformatics.net
.au/). The proportion of the length of each annotated gene covered by
reads was assessed for each isolate and a map summarizing all variable
genes and their distribution in each strain produced.
Variable nucleotide positions in Tn1549 for all VREfm isolates and
anaerobes were also identified, and a Tn1549 phylogeny was inferred us-
ing the neighbor-joining method with uncorrected P distances, as imple-
mented in SplitsTree v4.12.3 (46). In addition, the chromosomal Tn1549
insertion site was determined by aligning the contigs that spanned the left-
and right-hand ends of Tn1549 (obtained from de novo assembly of each
VREfm clone, as described above) to the AUS0004 reference genome.
Other features of the Tn1549 insertion that were determined included the
orientation of insertion within the chromosome and identification of the
5- to 8-bp coupling sequence. Separate clones of VREfm (unique VREfm
generation events) were defined as taxa with distinct core genome phy-
logenies, or if they possessed specific Tn1549 characteristics, they were
defined by including the variation in their transposon sequence, the in-
sertion site, the insertion orientation, or the coupling sequence. Differ-
ences in the pan genomes were also used to help define independent
VREfm clones.
Nucleotide sequence accession number. The sequence reads for all
isolates have been submitted to GenBank under BioProject identifier
PRJNA205886.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.00412-13/-/DCSupplemental.
Dataset S1, XLS file, 0.1 MB.
Dataset S2, XLS file, 0.1 MB.
Dataset S3, XLSX file, 1.1 MB.
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